Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy

Epilepsia

Volumn 37, Issue 8, 1996, Pages 774-780

  Sachdeo, Rajesh C ^a   Sachdeo, S K ^a   Walker, S A ^b   Kramer, L D ^b   Nayak, R K ^b   Doose, D R ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Carbamazepine; Drug interactions; Epilepsy; Pharmacokinetics; Topiramate

Indexed keywords

CARBAMAZEPINE; TOPIRAMATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; FEMALE; FOCAL EPILEPSY; HUMAN; KIDNEY CLEARANCE; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE;

EID: 0029845689     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00651.x     Document Type: Article

References (26)

1. Ramsay RE, Slater JD. Antiepileptic drugs in clinical development. Epilepsy Res 1993;10(suppl):45-67.
2. Sussman NM, Heydorn WE. New and investigational antiepilepsy drugs. Exp Opin Invest Drugs 1994;3:355-68.
3. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
4. Wu WN, Heebner JB, Streeter AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant, topiramate in healthy men [Abstract], Pharm Res 1994;11(suppl):S-336.
5. Nayak RK, Gisclon LG, Curtin CA, Benet LZ. Estimation of the absolute bioavailability of topiramate in humans with-out intravenous data [Abstract]. American College of Clinical Pharmacology 23rd Annual Meeting, Orlando, FL, October 1994, abs. no. 88.
6. Easterling DE, Zakszewski T, Moyer MD, et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans [Abstract]. Epilepsia 1988;29:662.
7. Liao S, Rosenfeld WE, Palmer M, et al. The steady-state pharmacokinetics of Topamax™ (topiramate) and valproic acid in patients with epilepsy on monotherapy, and during combination therapy [Abstract]. Pharm Res 1994;11(suppl): S-444.
8. Gisclon LG, Curtin CR, Kramer LD. A comparative study of the steady-state pharmacokinetics of phenytoin (Dilantin® Kapseals® brand) and of topiramate (Topamax®) in male and female epileptic patients on monotherapy, and during combination therapy [Abstract]. Pharm Res 1994;11(suppl):S-445.
9. Graves NM, Holmes GB, Fuerst RH, et al. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989;30:225-9.
10. Levy RH, Rettenmeier AW, Andersen GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48:225-35.
11. Eadie MJ. Formation of active metabolites of anticonvulsant drugs: a review of their pharmacokinetic and therapeutic significance. Clin Pharmacokinet 1991;21:27-41.
12. McKee PJW, Blacklaw J, Butler E, et al. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 1992;11:193-8.
13. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991;32: 716-21.
14. Cooper JM, Stubbs RJ, Palmer ME. A capillary GC assay with NPD detection for the quantification of topiramate in human plasma [Abstract]. AAPS 6th Annual Meeting and Exposition, Washington, D.C., November 1991. Pharm Res 1991;87(suppl 10):S19.
15. Crowder MJ, Hand DJ. Analysis of repeated measures. London: Chapman and Hall, 1990. (Monographs on statistics and applied probability; vol. 41.)
16. Conover WJ. Practical nonparametric statistics, 2nd ed. New York: John Wiley and Sons, 1980.
17. SAS user's guide: statistics, Cary, NC: SAS Institute.
18. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and war-farin metabolism in man. Clin Pharmacol Ther 1971;12:539-43.
19. Zielinski JJ, Haidukewych JJ. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 1987;9:21-3.
20. Browne TR, Szabo GK, Evans JE, et al. Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance. Neurology 1988;38:1146-50.
21. Wagner ML, Graves NM, Marienau K, et al. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991;32:398-406.
22. Muir KT, Palmer GC. Remacemide. Epilepsy Res 1991(suppl);3:147-52.
23. Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973;49:543-6.
24. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991;32:130-2.
25. Wagner ML, Remmel RP, Graves NM, et al. Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 1993;53:536-43.
26. Kramer LD, Pledger GW, Kamin M. Prototype antiepileptic drug clinical development plan. Epilepsia 1993;34:1075-84.